Roy Manning is an investor who attended college at SUNY(studied Pre-med) and then University of Wisconsin (studied banking, development planning and real-estate accounting). I am currently focusing on screening stocks in the Biotech, Pharmaceutical and Mining Stocks areas. I wish everyone success in investing.
Just another guy with a day job and an obsession with the stock market... my goal is to achieve FI (financial independence) by investing in growth and turnaround stocks.
I strive to provide actionable ideas that are capable of generating alpha for my readers, while never losing my sense of skepticism in the midst of the chaotic mix of euphoria and pessimism known as Wall Street.
Remember, there are no shortcuts. Do your own research, get your financial house in order, have your own sell rules, and check your ego at the door, as the market eventually humbles us all time and again.
Steven H. Goldman is a commercial litigation lawyer and senior partner in the Toronto law firm of Goldman Hine LLP. He is a former member of the board of directors of Tribute Pharmaceuticals Inc., a Canadian public pharmaceutical company which recently merged with Pozen Pharmaceuticals on February 5, 2016, and is now known as Aralez Pharmaceuticals (Nasdaq: ARLZ). He is currently on the board of directors of both Select Sands Corp. (TSX.V: SNS.V) as well as Comstock Metals Ltd. (TSX.V: CSL.V) which both trade on the TSX Venture exchange.
MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies (in partnership with Seeking Alpha). Licensed Investment Advisor. Top-ranked analyst on Tipranks.
Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform.
Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
I am professional with many years of experience in the pharmaceutical, biotech and device industry covering all functional areas from R&D to product commercialization. I write on Seeking Alpha regarding topics that I find interesting and focus on in depth financial and scientific research.
Independent writer/trader/investor that tends to write more for informational purposes than to advance a particular position. Please click to follow me if you like my work. There’s an option to follow me at the top of my articles. Best functionality of site is on desktop.
I’M NOT A FINANCIAL ADVISOR & ONLY GIVE MY OPINIONS. SEEK EXPERT ADVICE ELSEWHERE. ;) Investment Philosophy: Understand why you are getting in.
My positions, long or short can change dramatically as new information comes to my attention. All stocks are risky, but, don't follow me into a penny stock without realizing they are HIGHLY risky and you can lose ALL of your investment.
No payment in any form is accepted for my writing by any company or other party. I only receive that which comes from writing on Seeking Alpha.
Education is an undergraduate degree in Business Administration and Management. Masters' in Organizational Management.
Be kinder than necessary, for everyone you meet is fighting some kind of battle. ;)
We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
The long and short of it.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
We are not advisors.
I hold a PhD in the field of epidemiology a masters degree in public health. My undergraduate training is in policy, economics and the sciences. I have utilized my training in employment with government, academia, private industry and to further analyze the fundamentals and technicals of all manner of companies in different sectors. Specifically, I like to trade growth companies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies.
Each market day I get up at 530 am and begin working/analyzing data before my day job. I focus much on current events, earnings, and developments. I also work after market hours to cover after hours developments or interesting action during the day. I aim to conduct 2 analysis per business day, which helps me stay focused on my own finances.
I have been investing for about 10 years. I also enjoy trading short expiration options, and investing in stocks with 3-20 year horizons. I enjoy writing with Seeking Alpha to share my opinion and analyses. I am a large believer in the crowd source model championed by Seeking Alpha and believe every ounce of analysis and opinion should be considered when you invest your personal finances.
Spencer Osborne is founder of Satellite Standard Group [SSG], and a partner of Sirius Buzz (http://siriusbuzz.com/). Sirius Buzz covers the satellite radio industry as well as companies that do business in this sector. Sirius Buzz provides information and opinion to readers with an interest in the sector from an investment, as well as consumer perspective.
Along with his work in the media sector, Spencer covers various equities that interest him and writes about these equities from a unique and "out of the box" perspective. Over the years Spencer has built a network of resources within the sectors he writes about. His opinion and insight is oft referred to and sought after by analysts.
I take due diligence very seriously and I spend considerable time doing thorough research on companies and industries. I generally favour dividend stocks for the long term, but also trade short-term opportunities when I deem appropriate, generally for value companies. I have a background in Information Technology.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution. My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector. I am a contributing writer at CNA Finance and cover emerging opportunities as well as breaking news events.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
I’m a Pediatric Cardiac Anesthesiologist by trade with a keen interest in in-depth analyses of phenomena and processes which lead to clever solutions to technical and business challenges. I received a B.S. degree summa cum laude in Molecular Biophysics and Biochemistry from Yale College and an M.D. degree from Yale University School of Medicine; in addition, I hold M.S. degrees in Electrical Engineering, Mechanical Engineering, and Aeronautics and Astronautics from Stanford University School of Engineering.
Dan Rosenblum is the writer and editor of the Sharkbiotech.com (http://www.sharkbiotech.com) newsletter. His combination of a background in medical sales and as a full time trader for the last ten years give him a unique prospective in how to navigate the treaterous waters that is the biotech sector. He lives in New York with his wife and five children.
Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
I come from a background of Electrical Engineering. I enjoyed the creativity of working in the high-tech industry for 24 years, in design and managerial positions. In 2013 I decided to take a few years off from high-tech work, and concentrate on other areas of interest, including investing and stock analysis. I mostly invest in technology, and biotech, which I believe is the next revolution that is already underway, like computers were 20-50 years ago.
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
I am passionate about investing since 15 years already... and would like to share a couple of ideas with my readers.
I have an engineering background (PhD) and have worked in the industry bringing billions of dollars of manufacturing facilities up from the ground mainly holding a strategic/commercial role.
Please do your own research and due diligence prior to investing your own money. Good luck!
Nisha Hirani, M.D. is an experienced healthcare professional who serves as the Chief Scientific Advisor for Berg Capital Markets, LLC. In addition to her advisory role at Berg Capital Markets, LLC, Dr. Hirani currently works as a medical/healthcare industry consultant for NavMed Partners LLC. As a consultant, Dr. Hirani prepares proprietary client focused services including due diligence, valuation analysis, market research, and product research for biotechnology, pharmaceutical, healthcare staffing, healthcare IT and medical device companies, and is also a contributing writer for platforms such as Seeking Alpha and StockViews. Previously, Dr. Hirani worked as a biotechnology equity research analyst producing institutional quality equity research for under-valued and under-followed healthcare, biotechnology and medical device companies. Dr. Hirani’s initiating coverage reports, research reports and articles have been featured on both institutional and retail platforms including Thomson Reuters First Call, Bloomberg, Wall Street Source, Yahoo! Finance, Fidelity.com, and Google Finance. In the past, Dr. Hirani has taught embryology, performed research in the area of optical mammography, and taught English as a Second Language (ESL) classes. Dr. Hirani graduated from Tufts University with a B.S. in Biomedical Engineering and B.S in Biology, and received her Doctor of Medicine (M.D.) degree from St. George’s University School of Medicine. She completed her clinical clerkships primarily through the Barnabas Health System located in the New York Metropolitan area. In her free time, Dr. Hirani enjoys tennis, canvas painting, and volunteering for various non-profit organizations.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Financial markets have fascinated me since childhood. I strive to combine my education in biology, math and history with common sense to find winning trades.
To identify good investments and the right time to enter/exit them, I draw on all financial disciplines that could be helpful. The following is a non-exhaustive list that inform my decisions: Finances of a company, market condition, who owns it, what insiders are doing, analysis of trading behavior, option positions, short interest, public perception, social media, retail involvement, deep valuation of assets and patents, debts and obligations etc.
Btw, my screen name refers to the popular MODIS satellite package in polar orbit around earth. It's mission is to daily photograph the entire planet in several optical bands. This data that is then made available to researchers like biologists, which is how I know about it. It is my inspiration to try see things as they really are.
MODIS also reminds me of my favorite quote from Mr. Buffett: "It's easier to make up a lost opportunity, than to recover from a loss." The instrument moves on, seeing new things; it doesn't get stuck. Capital is a precious resource, so every trade deserves to be as perfect as you can make it.
I'm 32, invest in the light of the Austrian economic tradition, which in today's environment means mostly precious metals and mining stocks using cycles and sentiment as timing mechanisms. ETF's, options, I also own some physical. I've been doing this independently for 3 years. I reserve a small chunk of my portfolio for speculating in biotech and technology where I believe appropriate.
Harsh is well versed with secondary research on publicly-traded companies. He is experienced in evaluating fundamentals of companies and has written more than 700 investor-focused articles for various multimedia financial services companies in the U.S. He specializes in the technology sector (semiconductors) and has a good record of calling out companies as accurately as possible with a TipRanks rating among the top 100. Of late, he has started dabbling in the Energy sector.